Detection of anti-nucleocapsid antibodies associated with primary SARS-CoV-2 infection in unvaccinated and vaccinated blood donors
暂无分享,去创建一个
Marion C Lanteri | E. Grebe | P. Contestable | C. D. Germanio | Paula Saá | Valerie Green | Michael P. Busch | Steven Kleinman | ✦. M. Stone | Bryan R. Spencer | A. Akinseye | David J. Wright | Roberta L. Bruhn | Karla G. Zurita | B. Biggerstaff | Melissa M Coughlin | Brian Custer | Jefferson M. Jones
[1] C. V. von Bartheld,et al. An Explanation for Reports of Increased Prevalence of Olfactory Dysfunction with Omicron: Asymptomatic Infections. , 2023, The Journal of infectious diseases.
[2] B. Biggerstaff,et al. Evaluation of Ortho VITROS and Roche Elecsys S and NC Immunoassays for SARS-CoV-2 Serosurveillance Applications , 2023, Microbiology spectrum.
[3] Marion C Lanteri,et al. Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status — United States, April 2021–September 2022 , 2023, MMWR. Morbidity and mortality weekly report.
[4] O. Laeyendecker,et al. SARS‐CoV‐2 seroprevalence among blood donors in Uganda: 2019–2022 , 2023, Transfusion.
[5] Jens K. Boldsen,et al. Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in Denmark: A nationwide serosurveillance study , 2022, The Lancet Regional Health - Europe.
[6] N. Ohmagari,et al. Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants , 2022, Journal of Infection.
[7] D. Follmann,et al. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial , 2022, Annals of Internal Medicine.
[8] Jue Liu,et al. Percentage of Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A Systematic Review and Meta-Analysis , 2022, Vaccines.
[9] J. Opsomer,et al. Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021. , 2022, JAMA.
[10] P. Saá,et al. How do we …form and coordinate a national serosurvey of SARS‐CoV‐2 within the blood collection industry? , 2022, Transfusion.
[11] B. Biggerstaff,et al. Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications , 2022, Emerging infectious diseases.
[12] Samuel S. Shepard,et al. Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[13] Marcio K. Oikawa,et al. Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil , 2022, BMC Infectious Diseases.
[14] H. Ullum,et al. Long-term detection of SARS-CoV-2 antibodies after infection and risk of re-infection , 2022, International Journal of Infectious Diseases.
[15] A. Laxmaiah,et al. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June–July 2021: A population-based cross-sectional study , 2021, PLoS medicine.
[16] H. Whitaker,et al. Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off , 2021, medRxiv.
[17] E. Sabino,et al. Intense SARS-CoV-2 transmission among affluent Manaus residents preceded the second wave of the epidemic in Brazil , 2021, The Lancet Global Health.
[18] Noam Brown,et al. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. , 2021, JAMA.
[19] S. Kleinman,et al. Use of US Blood Donors for National Serosurveillance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Basis for an Expanded National Donor Serosurveillance Program , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] Weizhong Yang,et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study , 2021, The Lancet.
[21] Marcio K. Oikawa,et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic , 2020, Science.
[22] B. Custer,et al. Research initiatives of blood services worldwide in response to the covid‐19 pandemic , 2020, Vox sanguinis.
[23] S. Ladhani,et al. Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection , 2020, bioRxiv.
[24] K. Kim,et al. What Is COVID-19? , 2020, Frontiers for Young Minds.
[25] B. Gladen,et al. Estimating prevalence from the results of a screening test. , 1978, American journal of epidemiology.